Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-114822 · Präparat HOS-094169
Colchicine is a substrate of CYP3A4 and P-gp (an intestinal efflux transporter). Antibiotics Clarithromycin 500 mg Clarithromycin Cmax ↔ Whilst the changes in BID Clarithromycin AUC ↑ 19% clarithromycin parameters are not Clarithromycin Cmin ↑ 68% considered clinically relevant, the reduction in the 14-OH 14-OH-clarithromycin Cmax ↓ metabolite AUC should be 97% considered for the treatment of 14-OH-clarithromycin AUC ↓ infections caused by 97% Haemophilus influenzae in which 14-OH-clarithromycin Cmin ↓ the 14-OH metabolite is most 95% active. The increase of tipranavir Cmin may be clinically relevant. Tipranavir Cmax ↑ 40% Patients using clarithromycin at Tipranavir AUC ↑ 66% doses higher than 500 mg twice Tipranavir Cmin ↑ 100% daily should be carefully monitored for signs of toxicity of CYP 3A4 inhibition by clarithromycin and tipranavir. For tipranavir/r and P-gp (an patients with renal impairment intestinal efflux transporter) dose reduction of clarithromycin inhibition by clarithromycin. should be considered (see clarithromycin and ritonavir product information). Rifabutin 150 mg QD Rifabutin Cmax ↑ 70% Dosage reductions of rifabutin by Rifabutin AUC ↑ 190% at least 75% of the usual Rifabutin Cmin ↑ 114% 300 mg/day are recommended (ie 150 mg on alternate days, or 25-O-desacetylrifabutin Cmax ↑ three times per week). Patients 3.2 fold receiving rifabutin with Aptivus, 25-O-desacetylrifabutin AUC ↑ co-administered with low dose 21 fold ritonavir, should be closely 25-O-desacetylrifabutin Cmin ↑ monitored for emergence of 7.8 fold adverse events associated with rifabutin therapy. Further dosage Inhibition of CYP 3A4 by reduction may be necessary. tipranavir/r
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): Haemophilus influenzae (HOS-114823) rifabutin (HOS-086262) clarithromycin (HOS-084517) colchicine (HOS-086147) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 9364d701c0760ed3d66d44141af3d15e6dce638279d23ce5ea4706d31c6562cb · Zeichen 22090–25301 im Abschnitt